GTx, Inc. (GTXI) – Press Releases
-
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Clementia, Multi-Color, and GTx on Behalf of Stockholders and Encourages Investors to Contact the Firm
-
GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing a Diverse Pipeline of Novel Cancer Therapies
-
Recent Analysis Shows Automatic Data Processing, GTx, Ionis Pharmaceuticals, TriNet Group, Ternium S.A, and UNIVERSAL INSURANCE HOLDINGS INC Market Influences — Renewed Outlook, Key Drivers of Growt
-
GTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update
-
New Research Coverage Highlights Adesto Technologies, Pain Therapeutics, U.S. Global Investors, GTx, Columbus McKinnon, and Baytex Energy — Consolidated Revenues, Company Growth, and Expectations fo
-
GTx Announces Top-Line Results from Placebo-Controlled ASTRID Trial of Enobosarm in Women with Stress Urinary Incontinence
-
GTx, Inc. to Participate in the Baird 2018 Global Healthcare Conference
-
GTx Provides Corporate Update and Reports Second Quarter 2018 Financial Results
-
GTx Added to the Russell 3000® Index
-
GTx, Inc. to Participate in the Jefferies 2018 Global Healthcare Conference
-
GTx Updates Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at 2018 AUA Annual Meeting
-
GTx Provides Corporate Update and Reports First Quarter 2018 Financial Results
-
GTx to Present Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at a Podium Presentation at 2018 AUA Annual Meeting
-
GTx Announces Early Completion of Patient Enrollment in the ASTRID Trial, a Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence
-
GTx Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results
-
GTx Announced New Data Demonstrating Enobosarm’s Potential to Treat Stress Urinary Incontinence at SUFU 2018
-
GTx Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence Accepted for Podium Presentation at SUFU
-
GTx Provides Corporate Update and Reports Third Quarter 2017 Financial Results
-
GTx, Inc. to Participate in the Stifel 2017 Healthcare Conference
-
GTx Announces Closing of $48.5 Million Private Placement
-
GTx Announces $48.5 Million Private Placement
-
GTx Announces Webcast of Corporate Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference
-
GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York City
-
GTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence
-
GTx Provides Corporate Update and Reports Second Quarter 2017 Financial Results
-
GTx Discusses Key Goals with WSA
-
GTx Announces Positive Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence
-
GTx Provides Corporate Update and Reports First Quarter 2017 Financial Results
-
GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society Annual Meeting
-
GTx Announces Results from Preclinical Studies of SARMs in Duchenne Muscular Dystrophy Models Published in Human Molecular Genetics
-
GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results
-
GTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017
-
GTx Reports Results from Ongoing Enobosarm Phase 2 Clinical Trial in ER+/AR+ Breast Cancer
-
GTx, Inc. Announces 1-for-10 Reverse Stock Split
-
Enobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing Phase 2 Clinical Trial in ER+/AR+ Breast Cancer
-
GTx Announces Webcast of Corporate Presentation at the 28th Annual Piper Jaffray Healthcare Conference
-
GTx Achieves Second Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer
-
GTx Announces Webcast of Corporate Presentation at the Stifel 2016 Healthcare Conference
-
GTx Provides Corporate Update and Reports Third Quarter 2016 Financial Results
-
GTx Announces $14.0 Million Registered Direct Common Stock Offering
-
GTx Achieves Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer
-
GTx Announces Webcast of Corporate Presentation at Baird’s 2016 Healthcare Conference
-
GTx Appoints Dr. Garry Neil to Board of Directors
-
GTx Provides Corporate Update and Reports Second Quarter 2016 Financial Results
-
GTx Announces Webcast of Corporate Presentation at Jefferies 2016 Global Healthcare Conference
-
GTx Announces Webcast of Corporate Presentation at the UBS Global Healthcare Conference 2016
-
GTx Provides Corporate Update and Reports First Quarter 2016 Financial Results
-
GTx Announces Presentation of Preclinical Data Demonstrating the Ability of SARDs to Degrade and Inhibit the Androgen Receptor at the American Urological Association Annual Meeting
-
GTx, Inc. to Report First Quarter 2016 Financial Results on May 10, 2016
-
GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results
Back to GTXI Stock Lookup
